chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Pt received vaccine on 3/29/2004. Complained of arm hurt and achy that night. The next morning redness started. Continued to spread down arm about an inch from elbow, red, swollen, warm to touch. Zyrtec given to help and motrin.
I had a spike in blood pressure (150/104) with altered left upper visual field. My blood pressure has remained high but has been decreasing slightly
3 days after P7 and HIB, developed generalized seizure lasting 2-5 minutes. no fever; see in at ER. Within 24 hours of the onset of the first seizure had 3 more; requiring CPR; hospitalized; EEG nl. MRI results pending.
This spontaneous report was received from a consumer. The reported an article. This report refers to a 149 patients of unknown age and gender. On unknown dates, the patients were vaccinated with GARDASIL (dose, route, lot # and expiration date were not provided). On unknown dates, the patients died. The cause of death was not provided. It was unknown whether the autopsies were performed or not. This is one of several reports received from the same reporter. Additional information is not expected as reporter details were not provided.
This spontaneous case was reported by a patient and describes the occurrence of SCIATICA (Back and thigh pain due to sciatica is flaring- up), FEELING ABNORMAL (Feeling bad), BACK DISORDER (Back problems have recently worsened during the time) and CONDITION AGGRAVATED (Condition aggravated) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. Co-suspect product included non-company product DUPILUMAB (DUPIXENT) for Atopic dermatitis. The patient's past medical history included Back pain. Previously administered products included for Product used for unknown indication: Gabapentin. Past adverse reactions to the above products included No adverse event with Gabapentin. Concurrent medical conditions included Pruritus, Skin burning sensation, Pain in extremity, Sciatica, Neuropathy peripheral and Pain in thigh. In 2021, the patient started DUPILUMAB (DUPIXENT) (Subcutaneous) 300 milligram. On 07-Sep-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Sep-2021, DUPILUMAB (DUPIXENT) (Subcutaneous) dosage was changed to 600 milligram. On 08-Sep-2021, the patient experienced SCIATICA (Back and thigh pain due to sciatica is flaring- up). In September 2021, the patient experienced FEELING ABNORMAL (Feeling bad), BACK DISORDER (Back problems have recently worsened during the time) and CONDITION AGGRAVATED (Condition aggravated). At the time of the report, SCIATICA (Back and thigh pain due to sciatica is flaring- up) and CONDITION AGGRAVATED (Condition aggravated) outcome was unknown and FEELING ABNORMAL (Feeling bad) and BACK DISORDER (Back problems have recently worsened during the time) had not resolved. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown. On 22-Sep-2021, the patient started taking dupilumab at a loading dose of 600 mg once subcutaneously followed by maintenance dose of 300 mg every other week subcutaneously for atopic dermatitis. It was reported that patient was overworking her back and picking up heavy things at work; she recently started wearing a back brace while at work and has been doing Physical Therapy. Patient informed she takes gabapentin when her sciatic nerve problems flare but she had not been on gabapentin presently. No concomitant medication information was reported. No treatment medication information was reported. This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
Patient fainted 5 minutes or longer after vaccine was administered. Patient was waiting in the hallway until sibling had vaccines completed and when entering the room he became lightheaded and fainted. Patient was assisted to the floor and was aware of surroundings and walked to another room with assistance at side. Patient remained in room for 15 additional minutes and was offered juice and crackers. Patient tolerated fluids and was able to sit up and ambulate on own. Patient was released and left with sibling and mother.
This report to VAERS provides the following narrative: A report has been received from VAERS (Health Authority) concerning a 35 year old male patient. The patient's concurrent disease(s) included upper respiratory infection and erythromycin allergy. Patient had been received FLUMIST (Intranasal) started on 31-Aug-2009. It was reported that the patient developed Guillain-Barre shortly after receiving the flu via inhaled mist and for which he was hospitalized and continues to have minimal leg strength (in a wheelchair) and pain in arms/legs. Patient had inability to urinate, numbness in legs and tingling in extremities. Admitted to ICU, treatment IVF, LP, IVIG. The outcome of the event of Guillain Barre Syndrome was unknown. The reporter considered the event Guillain Barre Syndrome to be serious due to disability, life threatening and hospitalization. Laboratory values and diagnostic test details are available.
Onset of "flu" three days later: initially a sore throat, then a cough and quite a bit of upper respiratory congestion (Sunday through Thursday), with quite a bit of sleep required but some physical energy. Normal need for sleep has returned on Friday, still have lung and upper respiratory congestion and sore throat today, Saturday.
No adverse effect reported; one patient received an improperly stored VARlVAX; This spontaneous report was received from a nurse and concerns to a 4 year old patient of unknown gender. The patient's historical condition, and drug reactions or allergies were not reported. Concomitant therapies included sterile diluent.     On 13-AUG-2019,  the patient was vaccinated with an improperly stored dose of varicella virus vaccine live (oka/merck)(VARIVAX) (dosage schedule, route, anatomical location were not reported)(it can not be determined with which lot number was vaccinated the patient (R006221 and expiration date 29-FEB-2020 or R029517 and expiration date 14-OCT-2020)) for prophylaxis. The administered dose of the vaccine experienced a temperature excursion of -14 degrees Celsius to -10 degrees Celsius for 8 hours as recorded by a data logger. No previous temperature excursion was reported. There was no adverse effect reported.; Sender's Comments:  US-009507513-1909USA002960: US-009507513-1909USA006331: US-009507513-1909USA006332: US-009507513-1909USA006330: US-009507513-1909USA006334: US-009507513-1909USA006329: US-009507513-1909USA006328: US-009507513-1909USA006341:
Clinic was given by Health Department at our high school site. On the way back to our school, student complained of itching, throat feeling funny, and she began breaking out in hives
Really really bad Abdominal Cramping; Diarrhea; feels very weak; Nausea; Throwing up; Sore arm; Ranging Headache; A spontaneous report was received from a 23-year-old, female consumer who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced the events, ranging headache, sore arm, throwing up, diarrhea, nausea, really really bad abdominal cramping, and feels very weak.  The patients' medical history was not provided. Concomitant medications included escitalopram, buspirone and etonogestrel implant.  On 23 Dec 2020 at 13:30 approximately one hour prior to the onset of the events, the patient received their first of two planned doses of mRNA-1273 vaccine intramuscularly in the left arm for prophylaxis of COVID-19 infection.  On 23 Dec 2020 after vaccination, the patient experienced ranging headache and soreness on her arm. She had severe abdominal cramping in middle of the night.   On the morning of 24 Dec 2020 she began having diarrhea, nausea, really, really bad abdominal cramping and took 2 naproxen and warm bath after which she felt little better, but threw up immediately after. She also reported having to get up and down to go to the bathroom, but all that was coming out was water. She denied a fever. The patient attempted to go to urgent care during morning hours, but because she was experiencing COVID symptoms, healthcare provider stated they could not help her until she provided a negative COVID test result. The patient reported to have self-treated for her symptoms but continued to feel weak. Treatment for the events included naproxen and bismuth subsalicylate.  The event, ranging headache was considered resolved on 24 Dec 2020. The outcome of events, really really bad abdominal cramping, diarrhea, throwing up, feels very weak, and nausea, were considered not resolved. The outcome of the event, sore arm, was unknown.  Action taken with mRNA-1273 in response to the events was not provided.; Reporter's Comments: This case concerns a 23-year-old, female subject, who experienced a non-serious unexpected event of abdominal pain, diarrhea, asthenia and expected event of nausea, vomiting, injection site pain and headache. The event of headache and injection site pain within few hours after the first dose of mRNA-1273 (Lot# unknown) administration. The events of nausea, vomiting, abdominal pain, diarrhea and asthenia occurred 1 day 10 hrs. after the first dose of mRNA-1273 administration. Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Sore left arm after second Moderna Covid-19 vaccine; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Sore left arm after second Moderna Covid-19 vaccine) in an 86-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   In 2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In 2021, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. In 2021, the patient experienced PAIN IN EXTREMITY (Sore left arm after second Moderna Covid-19 vaccine). At the time of the report, PAIN IN EXTREMITY (Sore left arm after second Moderna Covid-19 vaccine) outcome was unknown.            No concomitant medication was reported by the reporter. No treatment was reported by the reporter.   Reporter did not allow further contact
Nausea; Vomiting; Itching; Headache; Blurry vision; This is a spontaneous report from a non-contactable healthcare professional, the patient. A 19-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 06Apr2021 at 12:00 (at the age of 19-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications included bupropion hydrochloride (WELLBUTRIN) and contraceptives (MANUFACTURER UNKNOWN) both from an unknown date for an unknown indication. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 06Apr2021 at 13:00, the patient experienced nausea, vomiting, itching, headache and blurry vision. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of the events included treatment with nausea medication. The clinical outcome of the events nausea, vomiting, itching, headache and blurry vision was not recovered at the time of the report.  No follow-up attempts are possible; information about the lot number cannot be obtained.
Dr. said when I asked him if he was ready for his #2 dose - he said no because for 5 days he had heart palpitations. First time that had ever happened to him. Kept an eye on it
2 days post injection general malaise; Injection site soreness 4 hours post injection; This is a spontaneous report from a non-contactable consumer, the patient. This elderly female patient of unknown age  received BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, lot number: EL 9265), dose 1 , single dose via an unspecified route of administration in the left arm on 26Jan2021 at 12:00 PM for COVID-19 vaccination. There was no relevant medical history. There were no known allergies. The patient was not pregnant.  Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive  any other vaccine within 4 weeks prior to the vaccine. On 26Jan2021 at 05:00 PM, the patient experienced injection site soreness 4 hours post injection. On 28Jan2021 2 days post injection, the patient had general malaise. No treatment was received for the events. The clinical outcome of injection site soreness and general malaise was recovered on an unknown date. It was also reported that since the vaccination, the patient had not been tested for COVID-19.   No follow up attempts are possible. No further information is expected.
This case was reported by a pharmacist via call center representative and described the occurrence of injection site pain in a 77-year-old male patient who received SHINGRIX (batch number G933B, expiry date 22nd November 2020) for prophylaxis. On 31st July 2018, the patient received the 2nd dose of SHINGRIX .5 ml. On 1st August 2018, 1 days after receiving SHINGRIX, the patient experienced fatigue. On an unknown date, the patient experienced injection site pain, injection site warmth, injection site swelling and injection site erythema. On an unknown date, the outcome of the injection site pain, injection site warmth and injection site swelling were not recovered/not resolved and the outcome of the fatigue was recovered/resolved and the outcome of the injection site erythema was unknown. It was unknown if the reporter considered the injection site pain, injection site warmth, fatigue, injection site swelling and injection site erythema to be related to SHINGRIX. Additional information was received as follows: At afternoon, the patient received SHINGRIX on the right arm. On 2nd July 2018, the patient called the pharmacist and reported that he had pain, redness and swelling in the injection site area. It was also hot to the touch. The patient described the redness and swelling area to be the circumference of a baseball. It was not known when these symptoms presented. The patient also said he felt the blahs on the day before the reporting date, which the pharmacy interpreted as fatigue.
pt became somnolent about 1/2 hr p/vax;pt brought to clinic;pt was awake when arrived @ clinic;
Sudden severe chills followed by excruciating leg muscle pain and cramping that lasted for hours. Stayed up all night watching the leg color and was concerned about blood clots.  Never felt anything like that before.  Horrible pain.  Exact same results from the Moderna booster on 4/29/22 at noon.  Approx 10 hours later chills and even worse that the first booster leg pain.  Only because I thought it would pass with the previous experience, I did not call an ambulance.  Feels like muscles are going to rupture if that is possible, I have no idea but it's not normal cramp.  Told doctor about the first episode and she never heard of that happening.
Numbness in bilateral hands/fingers; About 45 min she developed cyanosis of her right hand and fingers, same side were she received the vaccine.; Denies pain; SOB or chest pain.; SOB or chest pain.; This is a spontaneous report from a non-contactable healthcare professional. A 44-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 05May2021 (at the age of 44-years-old) as a single dose for COVID-19 immunisation. The medical history included gastroesophageal reflux disease (GERD), asthma and seafood allergy. Prior to vaccination, the patient was not diagnosed with COVID -19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The concomitant medications included pantoprazole sodium sesquihydrate (PROTONIX) and multivitamin(unspecified), all for unknown indications from unspecified dates and unknown if ongoing. On 05May201, about 45 minutes after the first dose vaccination, the patient developed cyanosis of her right hand and fingers, same side where she received the vaccine. On 10May2021, 5 days after the administration of the vaccine, the patient was still having the cyanosis and some numbness in bilateral hands/ fingers. The bilateral pulses were intact and oxygen saturation (O2) at room air was at 98%. On an unknown date in May2021, the patient denied pain, shortness of breath (SOB) or chest pain. On an unknown date in May2021, the patient underwent venous duplex test of right upper extremity and result was not reported. On an unknown date in May2021, the patient also underwent pulse rate check and the result revealed that it was intact and an oxygen saturation test at room air showed a result of 98%. The adverse events resulted in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events cyanosis of right hand and fingers, same side where she received the vaccine and numbness in bilateral hands/fingers were not  resolved, while the clinical outcome of pain, shortness of breath (SOB) or chest pain were unknown at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Initially just a sore arm almost immediately after vaccination. Then by the morning after the COVID-19 vaccination, extreme muscle and joint aches and horrible lethargy and a dull headache, all of  which lasted nearly 24 hours. Then starting three days following the vaccination soreness under the arm that the vaccination was given in the area of the lymph nodes. (Two things to note:  1-I donated blood on Feb. 8, 2021,  and the agency reported I had antibodies against COVID-19, probably due to an exposure in November 2020; after that exposure I had the mildest of upper respiratory symptoms, a very low grade fever and very achy joints for about a week and a half, but nothing that kept me from actively  working at home, and 2-I had traveled for work from Feb. 23-March 2, 2021, returning home two days prior to my first COVID vaccine on March 4. The day after I had returned home (March 3) I was very tired and achy, but by the next day I felt fine, so I went for my COVID vaccination. Perhaps my body's immune system was fighting off a re-exposure to COVID from the travel on March 3 and then I had the stress of the vaccine on the 4th which may have increased my reaction to the vaccine? )
patient completed 15 minute observation time without complications. returned approximately 1125 with c/o itchy rash. denied difficulty breathing, difficulty swallowing. vitals taken, MD notified. Orders to give diphenhydramine 25 mg PO and observe for 30 minutes for any other adverse affects. Patient symptoms improved, rash resolving, vitals stable, discharged with strict return instructions to ER, per MD if any other symptoms occurred.
w/in 24hr p/vax pt devel an inj site rxn characterized by an egg-sized area of redness, induration & burning;pt recovered p/2 days w/o tx;
Blood clot in left side of brain resulting in stroke and reduced functionality of the right side of my body.
No adverse effects were reported; Was administered a dose of VARIVAX and PROQUAD at the same visit; The patient was administered the first dose of PROQUAD too early; This spontaneous report was received from a medical assistant concerning a currently 12 year old patient. There was no information regarding the patient's medical history, concurrent conditions or concomitant medications.  On 05-NOV-2007, the patient was administered the first dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live(PROQUAD) for prophylaxis too early (dose, frequency, route of administration, anatomical location, lot number and expiration date were not provided). Since measles, mumps, rubella and varicella (oka-merck) virus vaccine live(PROQUAD) was administered too early it did not count on immunization records and the patient needed a dose of varicella and measles, mumps, and rubella (M-M-R II); instead, on 15-AUG-2019, the patient was vaccinated with the second dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live rHA(PROQUAD) lot # S008577 with expiration date of 16-SEP-2020, for prophylaxis and with a dose of varicella virus vaccine live (oka/merck)(VARIVAX) lot # R017638 with expiration date of 20-JUN-2020) for prophylaxis (dose, frequency, route of administration and anatomical location were not reported for none of both vaccines). Both, measles, mumps, rubella and varicella (oka-merck) virus vaccine live(PROQUAD) and varicella virus vaccine live (oka/merck)(VARIVAX) were reconstituted with sterile diluent(STERILE DILUENT) lot # N023666 with expiration date of 05-FEB-2020.
Headache, fever, body aches, 5-6cm edema, induration, erythema. No respiratory effects.
diagnosed as positive  COVID -19  on 11/24/21. Sign and symptoms included, increased general weakness with a fall, headache and nausea.
Rash, redness and itchiness in surrounding area around vaccine site and around my small pox vaccine scar
Severe fatigue began about 5 hours after injection on Saturday, followed by chills, body aches and night sweats the first and second night. Still had a pretty good appetite so it wasn't quite like the flu. The following day (Saturday) I experienced more fatigue, chills and a fever that went from 99 in the morning to 102 by late afternoon. I took 400mg of Advil when my fever was highest and was fine by Monday.  The injection site was also sore but not nearly as sore as the first dose.
received the first dose of the Covid vaccine on Monday 26Apr2021. On Wednesday 28Apr2021 he was tested positive for Covid-19; This is a spontaneous report from a contactable consumer. This consumer reported similar events for her husband and herself. This is the second of two reports for her husband. A 65-year-old male patient received BNT162B2(PFIZER-BIONTECH COVID-19 VACCINE), dose 1 via an unspecified route of administration on 26Apr2021 (Lot Number: ER8737; Expiration Date: 31Jul2021) as single dose for covid-19 immunisation.  The patient medical history included ongoing exposed prior to getting the vaccine. Concomitant medications were not reported.  The patient received the first dose of the Covid vaccine on Monday 26Apr2021. On Wednesday 28Apr2021 he was tested positive for Covid-19. He didn't know he had been exposed prior to getting the vaccine. He was exposed and didn't know it and then he got the symptoms. Patient's second shot was due 18 MAY 2021 and he will be cleared by the 08May2021.the outcome of the event was unknown.
Patient developed cellulitis at the site of the BEXSERO shot 5 days later. On the same day of shot developed tactile fever, severe headache, dizziness and poor concentration. Treatment was AUGMENTIN. Improving slowly.